Skip to main content
. 2022 Jun 8;41(10):3035–3047. doi: 10.1007/s10067-022-06218-8

Fig. 4.

Fig. 4

Cumulative probability of change from baseline in structural joint damage as measured by mTSS in patients from SPIRIT-P1 with PsA and treatment with ixekizumab Q4W as monotherapy or with concomitant MTX or any csDMARD (including MTX) at A 52, B 108, and C 156 weeks